Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
411 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02544633 | Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET | completed | Phase 2 | 68 | Mirati Therapeutics Inc.INDUSTRY | 9 | Mar 4, 2020 | clinicaltrials |
| NCT01118624 | Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer | completed | Phase 2 | 22 | Acrotech Biopharma Inc.INDUSTRY | 4 | Jan 7, 2020 | clinicaltrials |
| NCT00313170 | A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg(FINDER II) | completed | Phase 2 | 144 | AstraZenecaINDUSTRY | 8 | Jan 6, 2020 | clinicaltrials |
| NCT03023423 | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer(DARZALEX) | completed | Phase 1 / Phase 2 | 100 | Janssen Research & Development, LLCINDUSTRY | 5 | Nov 20, 2019 | clinicaltrials |
| NCT00401843 | A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 307 | Janssen Research & Development, LLCINDUSTRY | 18 | Nov 19, 2019 | clinicaltrials |
| NCT00721409 | Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer | completed | Phase 2 | 177 | PfizerINDUSTRY | 12 | Nov 4, 2019 | clinicaltrials |
| NCT02804750 | Study to Evaluate CORT125134 in Participants With Cushing's Syndrome | completed | Phase 2 | 35 | Corcept TherapeuticsINDUSTRY | 5 | Oct 15, 2019 | clinicaltrials |
| NCT01251536 | Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer(Everest2) | completed | Phase 2 | 108 | Universitaire Ziekenhuizen KU LeuvenOTHER | 5 | Oct 11, 2019 | clinicaltrials |
| NCT01204710 | A Study of Olaratumab (IMC-3G3) in Prostate Cancer | completed | Phase 2 | 123 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 20, 2019 | clinicaltrials |
| NCT01890746 | A Safety and Efficacy Study of Eltrombopag in Subjects With AML | completed | Phase 2 | 148 | Novartis PharmaceuticalsINDUSTRY | 10 | Sep 11, 2019 | clinicaltrials |
| NCT01327053 | A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma(BOLT) | completed | Phase 2 | 230 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 28, 2019 | clinicaltrials |
| NCT01867710 | Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy | completed | Phase 2 | 164 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 4 | Jul 5, 2019 | clinicaltrials |
| NCT01367665 | STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | completed | Phase 2 | 1,232 | Hoffmann-La RocheINDUSTRY | 37 | Jun 6, 2019 | clinicaltrials |
| NCT00869570 | External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer | completed | Phase 1 / Phase 2 | 54 | Swiss Cancer InstituteOTHER | 2 | May 15, 2019 | clinicaltrials |
| NCT01005199 | Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer | completed | Phase 2 | 106 | Swiss Cancer InstituteOTHER | 3 | May 15, 2019 | clinicaltrials |
| NCT02780167 | Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis | completed | Phase 2 | 269 | PfizerINDUSTRY | 5 | May 2, 2019 | clinicaltrials |
| NCT03109158 | NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 1 | NanoCarrier Co., Ltd.INDUSTRY | 4 | Apr 29, 2019 | clinicaltrials |
| NCT02083653 | Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer | completed | Phase 2 | 254 | Symphogen A/SINDUSTRY | 10 | Apr 16, 2019 | clinicaltrials |
| NCT02473952 | A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis | completed | Phase 2 | 62 | Grifols Therapeutics LLCINDUSTRY | 10 | Mar 5, 2019 | clinicaltrials |
| NCT00910091 | The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer | completed | Phase 2 | 73 | IpsenINDUSTRY | 12 | Jan 30, 2019 | clinicaltrials |
| NCT01210495 | Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma | completed | Phase 2 | 224 | PfizerINDUSTRY | 13 | Jan 9, 2019 | clinicaltrials |
| NCT02299635 | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations | terminated | Phase 2 | 19 | PfizerINDUSTRY | 6 | Jan 8, 2019 | clinicaltrials |
| NCT02633800 | Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN ) | terminated | Phase 2 | 87 | Daiichi SankyoINDUSTRY | 7 | Jan 7, 2019 | clinicaltrials |
| NCT01959282 | A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis | completed | Phase 2 | 219 | Janssen Research & Development, LLCINDUSTRY | 14 | Jan 4, 2019 | clinicaltrials |
| NCT02038647 | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 178 | Millennium Pharmaceuticals, Inc.INDUSTRY | 10 | Dec 27, 2018 | clinicaltrials |
| NCT02044822 | Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion | terminated | Phase 2 | 102 | Gilead SciencesINDUSTRY | 14 | Nov 19, 2018 | clinicaltrials |
| NCT00741260 | Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | completed | Phase 1 / Phase 2 | 105 | Puma Biotechnology, Inc.INDUSTRY | 11 | Sep 5, 2018 | clinicaltrials |
| NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer(NEFERTT) | completed | Phase 2 | 479 | Puma Biotechnology, Inc.INDUSTRY | 35 | Aug 22, 2018 | clinicaltrials |
| NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | completed | Phase 2 | 233 | Puma Biotechnology, Inc.INDUSTRY | 31 | Aug 9, 2018 | clinicaltrials |
| NCT01852292 | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | terminated | Phase 2 | 157 | Novartis PharmaceuticalsINDUSTRY | 18 | Jul 24, 2018 | clinicaltrials |
| NCT01234038 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel(NSCLC) | completed | Phase 1 / Phase 2 | 116 | Ionis Pharmaceuticals, Inc.INDUSTRY | 4 | Jun 27, 2018 | clinicaltrials |
| NCT02161419 | RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer(CONCEPT-SCLC) | terminated | Phase 2 | 142 | BayerINDUSTRY | 9 | Jun 25, 2018 | clinicaltrials |
| NCT00890825 | AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients | completed | Phase 2 | 88 | AstraZenecaINDUSTRY | 12 | Jun 20, 2018 | clinicaltrials |
| NCT01113957 | A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer | completed | Phase 2 | 168 | AbbVie (prior sponsor, Abbott)INDUSTRY | 8 | Jun 6, 2018 | clinicaltrials |
| NCT02273973 | A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) | completed | Phase 2 | 334 | Genentech, Inc.INDUSTRY | 22 | May 21, 2018 | clinicaltrials |
| NCT00266877 | Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 172 | Puma Biotechnology, Inc.INDUSTRY | 5 | Apr 13, 2018 | clinicaltrials |
| NCT01024036 | A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease | completed | Phase 2 | 79 | Janssen Research & Development, LLCINDUSTRY | 23 | Mar 21, 2018 | clinicaltrials |
| NCT01453205 | A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 2 | 187 | MedImmune LLCINDUSTRY | 11 | Mar 12, 2018 | clinicaltrials |
| NCT02971319 | Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma | completed | Phase 2 | 32 | Proactina S.A.OTHER | 2 | Jan 26, 2018 | clinicaltrials |
| NCT00500292 | A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer | completed | Phase 2 | 109 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Jan 25, 2018 | clinicaltrials |
| NCT02131662 | Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap(ASTEROID 1) | completed | Phase 2 | 309 | BayerINDUSTRY | 13 | Dec 8, 2017 | clinicaltrials |
| NCT01385748 | Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis | completed | Phase 2 | 183 | Valerio TherapeuticsINDUSTRY | 6 | Nov 28, 2017 | clinicaltrials |
| NCT00868608 | Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma | completed | Phase 2 | 81 | PfizerINDUSTRY | 9 | Oct 31, 2017 | clinicaltrials |
| NCT01004003 | Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 125 | Boehringer IngelheimINDUSTRY | 8 | Oct 26, 2017 | clinicaltrials |
| NCT00101998 | Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication | completed | Phase 2 | 233 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 26 | Aug 30, 2017 | clinicaltrials |
| NCT00472420 | A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma. | completed | Phase 2 | 48 | Hoffmann-La RocheINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials